Genetic profiling and pathway analysis in bladder carcinoma: Implications for therapeutic targeting

Our plain-English summary of Genetic profiling and pathway analysis in bladder carcinoma: Implications for therapeutic targeting, by S. Vasishta, U.S. Adiga, A.J. Augustine (Turkish Journal of Surgery, 2025).

The study

• Authors: S. Vasishta, U.S. Adiga, A.J. Augustine
• Journal: Turkish Journal of Surgery
• Published: 2025;41(4):437-447
• Cited by: 2 articles, as counted by NIH iCite
• Read it: PubMed · Publisher · Free full text

Abstract

Objective: Bladder carcinoma represents a significant challenge in oncology due to its heterogeneous molecular nature. This study aimed to identify key genetic factors and molecular pathways involved in bladder carcinoma pathogenesis to facilitate the development of targeted therapies.

Material And Methods: The top 30 genes associated with bladder carcinoma were retrieved from the disease gene network database. Comprehensive bioinformatic analysis was performed using various enrichment tools, including gene ontology biological process, cellular component, molecular function analyses, and pathway mapping through WikiPathways and metabolite associations through human metabolome database. Drug interactions were evaluated using DrugMatrix data.

Results: Gene ontology analysis revealed significant enrichment of cancer-related biological processes, cellular components, and molecular functions. Pathway analysis identified strong associations with head and neck squamous cell carcinoma, cancer pathways, pleural mesothelioma, endometrial cancer, and bladder cancer pathways. Key genes including CDKN2A, PTEN, EGFR, PIK3CA, HRAS, FGFR3, and TP53 were implicated across multiple pathways. Metabolite analysis showed significant associations with phosphatidylinositol derivatives, highlighting the importance of the PI3K pathway. Drug interaction analysis revealed potential modulatory effects of several compounds including sertraline, valproic acid, and hydroxyurea on gene expression patterns in bladder carcinoma.

Conclusion: This study provides comprehensive insights into the molecular underpinnings of bladder carcinoma, highlighting interconnected pathways and potential therapeutic targets. The significant overlap with other cancer types suggests common oncogenic mechanisms that could be exploited for therapeutic intervention. Further validation of these findings in clinical samples may facilitate the development of personalized treatment approaches for bladder carcinoma patients.

Copyright© 2025 The Author(s). Published by Galenos Publishing House on behalf of Turkish Surgical Society.

In plain English

This was a computer-based (bioinformatic) analysis of bladder carcinoma using public databases. It involved no patients, and it did not study asbestos or any other exposure. The authors took the top 30 genes linked to bladder carcinoma in the DisGeNET database. They then checked which known biological pathways, cell functions, metabolites and drug effects those genes overlapped with. The pathway most strongly over-represented was head and neck squamous cell carcinoma, with 15 of the 30 genes. A pathway labelled pleural mesothelioma contained 18 of the 30 genes, and a bladder cancer pathway contained 9. The mesothelioma result reflects genes shared in a database. It is not a finding about mesothelioma patients or what causes the disease. Genes including CDKN2A, PTEN, EGFR, PIK3CA, HRAS, FGFR3 and TP53 recurred across pathways. The drug data came from rat studies. In rat liver cells, sertraline was linked to lower expression of five of the genes, with an adjusted p-value of 0.07. The authors concluded these genes are potential treatment targets. They noted that their analyses show statistical associations, not causes, and need checking in bladder-specific systems.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Bioinformatic secondary analysis of public databases (gene, pathway, metabolite and drug-expression enrichment analysis); no human or animal subjects studied directly
• Who was studied: No people were studied. The analysis used the top 30 genes associated with bladder carcinoma in the DisGeNET database, ranked by DisGeNET's association score
• Exposure: None studied. The article examines database genes linked to bladder carcinoma and does not mention asbestos or any fiber; drug effects came from rat data in the DrugMatrix database
• Main results:
  • The most strongly enriched pathway was head and neck squamous cell carcinoma: 15 of the 30 bladder carcinoma genes mapped to it (adjusted p-value 3.09 × 10 to the minus 27)
  • A 'cancer pathways' set contained 20 of the 30 genes (adjusted p-value 3.51 × 10 to the minus 23)
  • A pathway labelled pleural mesothelioma contained 18 of the 30 bladder carcinoma genes (adjusted p-value 7.36 × 10 to the minus 18). This is an overlap of genes in a pathway database, not data on mesothelioma patients
  • A bladder cancer pathway contained 9 of the 30 genes (adjusted p-value 1.37 × 10 to the minus 10)
  • An ATM-dependent DNA damage response pathway contained 12 of the 30 genes (adjusted p-value 2.09 × 10 to the minus 12)
  • The most strongly associated metabolite, C11H19O13P (HMDB06953), a phosphatidylinositol-related compound, was linked to three genes (PIK3CA, PTEN, PIK3CG), with adjusted p-value 0.00023 and odds ratio 92.34
  • In rat drug-expression data, sertraline (23 μM, primary rat hepatocytes) was associated with lower expression of five genes (GSTM1, CDH1, AKT1, TTN, VEGFA), adjusted p-value 0.07, odds ratio 13.34. Valproic acid, hydroxyurea and other drugs showed similar associations in rat liver
• The authors' conclusion: The authors concluded that genes including CDKN2A, PTEN, EGFR, PIK3CA, HRAS, FGFR3 and TP53 are central nodes in the bladder carcinoma gene network and potential therapeutic targets. They concluded that the overlap with other cancer types suggests shared cancer mechanisms, and that the findings need validation in clinical samples
• Limitations the authors state:
  • The DisGeNET database may not capture all genes relevant to bladder carcinoma
  • Enrichment analyses show statistical associations and do not establish causal relationships
  • Drug interaction findings come from non-bladder tissues or animal models and need validation in bladder-specific systems
  • The study did not examine how the genes relate to established molecular subtypes of bladder cancer, such as luminal and basal

Topics

Medical terms in this study, explained in our Lexicon: Carcinoma, Squamous Cell Carcinoma, Pleural Mesothelioma, CDKN2A, EGFR.

Related studies

• Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implications — M.B. Suraokar, M.I. Nunez, et al. (2014)
• BAP1 Mutations and Pleural Mesothelioma: Genetic Insights, Clinical Implications, and Therapeutic Perspectives — S. Cedres, A. Valdivia, et al. (2025)
• Targeting the Hippo Pathway Is a New Potential Therapeutic Modality for Malignant Mesothelioma — Y. Sekido (2018)
• Preventive and therapeutic opportunities: targeting BAP1 and/or HMGB1 pathways to diminish the burden of mesothelioma — M. Carbone, M. Minaai, et al. (2023)
• The Crosstalk between FAK and Wnt Signaling Pathways in Cancer and Its Therapeutic Implication — J. Wörthmüller, C. Rüegg (2020)
• Molecular genetics and mechanisms of apoptosis in carcinomas of the lung and pleura: therapeutic targets — L.R. Motadi, N.L. Misso, et al. (2007)

Browse return to medical research.